Sold under the brand name Lumakras and Lumykras, Sotorasib targets the common mutation G12C in KRAS protein associated with various forms of cancers. It is an inhibitor of RAS gtpase family of protein and used to treat non-small-cell lung cancer (NSCLC). Here, KRAS is linked to cancer.